. 2014 Feb 17;25(6):517–528. doi: 10.1089/hum.2013.196

Table 1.

Scoring of Lung Inflammation After Perinatal rAAV2/5 Administration or Readministration in Adult Life^a

	Diffuse (sub-) mucosal infiltrate: central airways	Diffuse (sub-) mucosal infiltrate: peripheral airways	Alveolar/venous infiltrate
Neg control	0±0	0±0	0±0
Non-readmin^b
Fetal	0±0	0.4±0.8	0.5±0.7
Neonatal	0.5±1.0	0.3±0.5	0.4±0.5
Readmin^c
Fetal	1.3±1.2	1.7±1.5	1.3±1.2
Neonatal	1.7±0.6	1.8±1.3	2.0±1.0
Adult control	2.0±1.0	1.7±0.6	0.8±0.3

Neg, nontreated; Readmin, readministration at 3 months and tissue collection at 4 months; Non-readmin, non-readministered controls 4 months after perinatal gene transfer.

^{^a}

Lung sections were stained with hematoxylin and eosin and scored to evaluate the degree of lung inflammation after fetal and neonatal rAAV2/5 administration (1.0×10¹⁰ GC of rAAV2/5-β-Gal per animal; 1.5×10¹⁰ GC of rAAV2/5-fLUC per animal) and readministration at 3 months. Lung sections were scored according to the region as well as the degree of inflammation. Scores: 0, no immune cell infiltration; 0.5, few infiltrating cells with minimal significance; 1, mild lymphocytic infiltrate; 2, moderate lymphocytic infiltrate; 3, severe lymphocytic infiltrate. Data represent means±SD.

^{^b}

Non-readministration controls for the fetal and neonatal group 4 months after perinatal rAAV2/5 delivery.

^{^c}

Readministration animals for the fetal and neonatal group 1 month after readministration.